VIDAS® B•R•A•H•M•S PCT™

Helping you manage antibiotic therapy in LRTI*

BIOMÉRIEUX

BECAUSE IT MAKES SENSE ON VIDAS®

● On-demand testing adapted to Primary Care and Emergency settings

● Rapid result: only 20 minutes● Automated test on easy-to-use benchtop instrument

● Cost-effi cient solution: 1 patient = 1 test

PRESCRIBE ANTIBIOTICS – OR NOT – WITH CONFIDENCETo reduce antibiotic exposure and side eff ects and improve survival, you can count

on VIDAS® B•R•A•H•M•S PCT™. It has been validated in a clinical setting

for the management of antibiotic therapy in LRTI* patients 12.

Numerous international, multi-center, randomized control studies have shown

that PCT-guided antibiotic therapy in LRTI* is safe and eff ective 13,14.

Signifi cant reduction was observed in the PCT groups vs. the control groups in:

● antibiotic initiation: 70% vs 86%

● antibiotic treatment duration: 8 days vs 9.4 days

● total antibiotic exposure: 5.7 days vs 8.1 days

● antibiotic-related side eff ects: 16% vs 22%

● mortality at 30 days: 9% vs 10%0

20

40

60

80

Patie

nts

on a

ntib

iotic

s (%

)

100

Day 0

86%

71%

0

2

4

6

8

Patie

nts

on a

ntib

iotic

s (%

)

10A B

Overall

8.14

50.71

82%

63%

71%

51%

58%

36%41%

23%27%

16% 18%

11% 13%8%

Day 2 Day 4 Day 6 Day 8 Day 10 Day 12 Day 14

Control groupProcalcitonin group

PCT reduces antibiotic exposure and treatment duration14

A - Proportion of patients on antibioticsB - Mean duration of antibiotic use

Give antibiotics to the right patients, at the right time, for the right duration

VIDAS® B•R•A•H•M•S PCT™

Helping you manage antibiotic therapy in LRTI*

Did you know?

The Challenge of LRTI* Management: Does Your Patient Really Need Antibiotics?

How does Procalcitonin (PCT) Provide Critical Information?

Many diff erent forms:• Acute bronchitis• Community-Acquired Pneumonia

(CAP)• Acute exacerbation of chronic

obstructive pulmonary disease (COPD)

* LRTI: Lower Respiratory Tract Infections.

Monitoring antibiotic treatment with serial PCT measurementsAdapted from Brunkhorst FM.9

A host biomarker specifi c for severe bacterial infection 7-10

PCT is produced by numerous organs at a cellular level afterbacterial pro-infl ammatory stimulation 5,6. Its expression is inhibited by viral infections.• Rises within 3-6 hours from bacterial insult• Daily decrease of 50% as infection is resolved• Proven to aid in monitoring patient response to antibiotic therapy 11

In the past, this challenge was met with empiric antibiotic therapy, resulting in:• Antibiotic misuse• Inappropriate initiation and prolonged use• Antibiotic-associated infections such as Clostridium di� cile,

and other adverse eff ects3,4

• Increasing antimicrobial resistance

Today, a valuable diagnostic tool can help you decide if antibiotics are warranted and optimize treatment duration.

Non-specifi c clinical characteristics:• Cough• Sputum• Fever• Shortness of breath

LRTI* account for 10% of the worldwide burden of morbidity and mortality1

01 2 3 4 5 6

5

10

15

20

PCT

ng/m

l

Days

Consider treatmentfailure

Treatment success

25

75% of all antibiotic doses worldwide are prescribed for acute respiratory tract infections in spite of mainly viral cause1

50% of antibiotics prescribed in the US for acute respiratory conditions are unnecessary2

START ANTIBIOTICS OR NOT?Recommendations to start antibiotics 12:

WHEN TO STOP ANTIBIOTICS?Testing PCT at regular intervals*** combined with clinical assessments can support decision-making on antibiotic discontinuation for patients with LRTI*: If PCT ≤ 0.25 ng/mL Discontinue antibiotics 12

For cases of sepsis in the ICU: If PCT < 0.5 ng/mL (or PCT drop ≥ 80%) Discontinue antibiotics 11

Consider continuing antibiotics in presence of clinical instability or disease progression. If PCT remains high, consider treatment failure.

SUPPORTING HOSPITAL COST OPTIMIZATIONSeveral health economics studies have shown that PCT-guided antibiotic strategies in LRTI* are cost-effective in different settings: primary care, intensive care units and emergency departments.

PCT value

Bacterial infection**

Initiation of antibiotic therapy

< 0.1 ng/mL 0.1-0.25 ng/mL 0.26-0.5 ng/mL > 0.5 ng/mL

Absent Unlikely Possible Suggestive

Strongly discouraged Discouraged Recommended Strongly

recommended

“Use of sensitive procalcitonin measurements in clinical algorithms can reduce antimicrobial overuse, decreasing the risk of side effects and controlling emerging bacterial multiresistance.”Schuetz P, et al. Overview of procalcitonin assays and procalcitonin-guided protocols for the management of patients with infections and sepsis. Expert Review of Molecular Diagnostics 2017;17(6):593-601.

“PCT may be safely incorporated into treatment algorithms for children with CAP to reduce antibiotic administration and duration.”Stockman et al. Procalcitonin Accurately Identifies Hospitalized Children with Low Risk of Bacterial Community-Acquired Pneumonia. Journal of The Pediatric Infectious Diseases Society 2017 Feb 3.doi:10.1093.

“Given the prevalence of COPD and the duration of illness, a reduction in antibiotic prescriptions for the treatment of exacerbations could have a tremendous impact on the overall economic burden of the disease under current budget constraints. In addition, the controlled prescription of antibiotics decreases selective pressure for the emergence of bacterial resistance.”Stolz D, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131(1):9-19.

“Good compliance with the PCT algorithm is possible in real-life conditions but has to be reinforced to achieve optimal benefit.”Albrich WC, et al. Effectiveness and Safety of Procalcitonin-Guided Antibiotic Therapy in Lower Respiratory Tract Infections in “Real Life”: An International, Multicenter Poststudy Survey (ProREAL). Arch Intern Med 2012;172(9):715-722.

Discover more about PCT and antimicrobial stewardship:

VIDAS® B•R•A•H•M•S PCT™

HELPS YOU IMPROVE ANTIBIOTIC STEWARDSHIP

$6M USD 15

$1.6M USD 18

(1.1b Chilean pesos)

$0.5M USD 16

(3.4M CNY)

$73M USD 17 (53M€)

COPD patients only

PROCALCITONIN-GUIDEDANTIBIOTIC THERAPY

Selection of publications2018 EDITION

Estimated total annual savings when using a PCT algorithm ** Adapted from VIDAS® B•R•A•H•M•S PCT™ package insert*** Every other day or every 2 days, depending on the patient evolution.

AVAILABLE ON http://www.biomerieux-diagnostics.com or from your local bioMérieux representative

02-1

8/ 9

3147

93/0

08/G

B/A

/ B•

R•A•

H•M

•S P

CT is

the

prop

erty

of T

herm

o Fi

sher

Sci

enti�

c In

c an

d its

sub

sidi

arie

s /

Docu

men

t and

/or p

ictu

res

not l

egal

ly b

indi

ng. M

odi�

catio

ns b

y bi

oMér

ieux

can

be

mad

e w

ithou

t prio

r not

ice

/ BI

OM

ERIE

UX,

the

BIO

MER

IEU

X lo

go a

nd V

IDAS

are

use

d, p

endi

ng a

nd/o

r reg

iste

red

trad

emar

ks b

elon

ging

to b

ioM

érie

ux, o

r one

of i

ts s

ubsi

diar

ies

or o

ne o

f its

com

pani

es. A

ny o

ther

trad

emar

k is

the

prop

erty

of i

ts re

spec

tive

owne

r. VI

DAS

appa

ratu

s is

a u

sed,

pen

ding

and

/or r

egis

tere

d de

sign

s be

long

ing

to b

ioM

érie

ux o

r one

of i

ts c

ompa

nies

/ b

ioM

érie

ux S

.A. R

CS Ly

on 6

73 6

20 3

99 /

Prin

ted

in F

ranc

e /

ther

a/ R

CS Ly

on B

398

160

242

AVAILABLE ON INSTRUMENTS OFTHE VIDAS® FAMILY:VIDAS®, MINI VIDAS®

AND VIDAS® 3

VIDAS® B•R•A•H•M•S PCT™VIDAS® ACUTE CARE PANEL

B•R•A•H•M•S PCT™

D-Dimer Exclusion™ II High sensitive Troponin I NT-proBNP2 Galectin-3 CK-MB Myoglobin Digoxin

Discover the VIDAS community and become

a member by registering on www.myvidas.com

bioMérieux S.A. • 69280 Marcy l’Étoile • France • Tel.: + 33 (0)4 78 87 20 00 • Fax: +33 (0)4 78 87 20 90www.biomerieux.com • www.biomerieux-diagnostics.com

Reference number 30450

Tests / kit 60

Time to result 20 minutes

Sample type Serum, Plasma (Lithium heparinate)

Sample volume 200 µL

Measuring range 0.05 - 200 ng/mL

Calibrators & Controls frequency Every 28 days

REFERENCES 1. Christ-Crain M, et al. Lancet 2004; 363-600-607. 2. Fleming-Dutra KE, et al. JAMA. 2016 May 3;315(17):1864-73. 3. Antibiotics – side eff ects. NHS Choices. http://www.nhs.uk/Conditions/Antibiotics-penicillins/ Pages/Side-eff ects.aspx. Accessed February 15, 2017. 4. Lessa FC, et al. N Engl J Med. 2015; 372:825-834. 5. Kumar A, et al. Crit Care Med. 2006;34(6):1589-1596. 6. Müller B, et al. J Clin Endocrinol Metab. 2001;86(1):396-404. 7. Harbarth S, et al. Am J Respir Crit Care Med 2001;164(3):394-402. 8. Müller B, et al. Crit Care Med. 2000;28(4):977-983. 9. Brunkhorst, et al. Intensive Care Med. 1998;24(8):888-889. 10. Meisner M. J Lab Med. 1999;23:263-272. 11. Schuetz P. et al. Arch of Int Medicine 2011;171(15):1322-1331. 12. Albrich WC, et al. Arch Intern Med. 2012;172(9):715-722. 13. Schuetz P., et al. Cochrane Database Syst Rev. 2017;10:CD007498. doi: 10.1002/14651858.CD007498. 14. Schuetz P., et al. Lancet Infect Dis. 2017 S1473-3099(17)30592-3. 15. Schuetz P, et al. Clin Chem Lab Med. 2015 Mar;53(4):583-92. 16. Stojanovic I, et al. Clin Chem Lab Med. 2016 Sep 22. doi: 10.1515/cclm-2016-0349. 17. Van Der Maas et al. Omics: Journal of Integrated Biology Vol21, Number 4, 2017. 18. Schneider JE et al. Value in Health 19 (2016) A1-A318.

IMPORTANT INFORMATIONVIDAS® B•R•A•H•M•S PCT™ (PCT) is not indicated to be used as a standalone diagnostic assay and should be used in conjunction with clinical signs and symptoms of infection and other diagnostic evidence.Decisions regarding antibiotic therapy should NOT be based solely on procalcitonin concentrations. PCT results should always be interpreted in the context of the clinical status of the patient and other laboratory results.

BIOMÉRIEUX